Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | ROS1 | P08922 | 2/20 | 0.38 |
| ▸ | LIMK1 | P53667 | 6/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | LIMK2 | P53671 | 4/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16184332 | 0.93 | NPC1 (0.47) | NPC1RAB9AROS1LIMK1MAPK14 | |
| SCHEMBL16184324 | 0.89 | CYP1A2 (0.44) | NPC1RAB9ALIMK1MAPK14LIMK2 | |
| SCHEMBL14474740 | 0.89 | NPC1 (0.42) | NPC1RAB9ACYP11B2CASP6GPBAR1 | |
| SCHEMBL16184325 | 0.88 | NPC1 (0.42) | NPC1RAB9ACYP11B2ABL1CASP6 | |
| SCHEMBL16184318 | 0.88 | NPC1 (0.41) | NPC1RAB9ACYP11B2ABL1CASP6 | |
| SCHEMBL16184337 | 0.87 | NPC1 (0.41) | NPC1RAB9ALIMK1MAPK14LIMK2 | |
| SCHEMBL16184331 | 0.86 | NPC1 (0.40) | NPC1RAB9ALIMK1MAPK14LIMK2 | |
| SCHEMBL16184333 | 0.86 | NPC1 (0.40) | NPC1RAB9ALIMK1MAPK14METAP2 | |
| SCHEMBL14474746 | 0.86 | NPC1 (0.39) | NPC1RAB9ALIMK1MAPK14LIMK2 | |
| SCHEMBL16184335 | 0.86 | NPC1 (0.41) | NPC1RAB9ALIMK1MAPK14LIMK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | NPC1 2208/4885RAB9A 1340/4885ROS1 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.